



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 54704.8036.US03 (UMD-0072)  
Inventors: John Langenfeld  
Serial No.: 10/692,824  
Filing Date: October 23, 2003  
Examiner: Stephen L. Rawlings  
Customer No.: 46046  
Group Art Unit: 1643  
Confirmation No.: 1322  
Title: Bone Morphogenetic Protein-2 in the  
Treatment and Diagnosis of Cancer

"Express Mail" Label No. EV688860799US  
Date of Deposit: February 17, 2006

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Commissioner for Patents, Mail Stop AF,  
P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

( ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

(XX) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) Reference DA is in a foreign language and an English Abstract is provided and Reference DB is in the English language.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: **February 17, 2006**

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

|  |    |   |                                 |
|--|----|---|---------------------------------|
| <b>Form PTO-1449 Modified</b>  |    | <b>Docket No.</b><br>54704.8036.US03 (UMD-0072)   | <b>Serial No.</b><br>10/692,824 |
| <b>List of Patents and Publications<br/>Cited by Applicant<br/>(Use several sheets if necessary)</b><br><br><b>U.S. Department of Commerce</b> |    | <b>Applicant</b><br><b>John Langenfeld</b>  |                                 |
|  |    | <b>Filing Date</b><br><b>October 23, 2003</b>   | <b>Group</b><br><b>1642</b>     |
| <b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>  |    |   |                                 |
|  | DA | Meric et al., "Zd 1839 "Iressa"", Bull Cancer 2000<br>87(12):873-876  |                                 |
|  | DB | Sirotnak et al., "Co-administration of Probenecid, an Inhibitor of a<br>cMOAT/MRP-like Plasma Membrane ATPase, Greatly Enhanced the Efficacy of a<br>New 10-Deazaaminopte against Human Solid Tumors <i>in Vivo</i> ", Clinical Cancer<br>Research 2000 6:3705-3712 |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
|  |    |   |                                 |
| <b>EXAMINER</b>  |    | <b>DATE CONSIDERED</b>  |                                 |